

DAVID C. WILSON, M.D.

Born: Atlanta, Georgia

June 9, 1956

U.S. Citizen

License #0101-037565

Education:

- 1985-1988** **Dermatology**
Vanderbilt University Medical Center
Nashville, Tennessee
Residency (Chief Resident, July 1987 - June 1988)
- 1982-1985** **Internal Medicine**
Baylor College of Medicine Affiliated Hospitals
Houston, Texas
Residency
- 1982** **Medical College of Virginia**
Richmond, Virginia
M.D.
- 1978** **Wake Forest University**
Winston-Salem, North Carolina
B.A. (Chemistry)
Magna Cum Laude, Phi Beta Kappa

Experience:

- 1992-Present** **Study Investigator**
The Education & Research Foundation, Inc. (ERF)
2095 Langhorne Road, Lynchburg, Virginia 24501
- 08/2017-Present** **Private Practice, Dermatology Consultants**
Lynchburg, Virginia
- 1992-07/2017** **Private Practice, Central Virginia Dermatology**
Lynchburg, Virginia
- 1988-1992** **Assistant Professor**
Department of Medicine/Division of Dermatology
Vanderbilt University Medical Center
Nashville, Tennessee

Memberships:

- 1998-Present** American Academy of Dermatology
- 1992-Present** Lynchburg Academy of Medicine
- 1990-Present** Southern Medical Association

Publications:

Articles:

1. King LE Jr., **Wilson DC**: Erythroderma: Establishing etiology and choosing therapy. *Modern Medicine* 57:80, 1989.
2. **Wilson DC**, King LE Jr: Spiders and Spider Bites. *Dermatology Clinics* 8:277, 1990.
3. Gross AS, **Wilson DC**, King LE Jr: Persistent Segmental Cutaneous anesthesia following a brown recluse spider bite. *South. Med. J.* 83:1321, 1990.
4. **Wilson DC**, Werth S, King LE Jr: Ulceration Herpes Simplex Type II in a patient with Evan's syndrome. *South. Med. J.* 83:1484, 1990.
5. Werth S, Latour D, **Wilson DC**: Yellow Plaques and Skin Ulcerations in a Cardiac Transplant Patient. *Arch. Dermatol.* 128:547, 1992
6. Wharton M, Wadley FS, Hager B, **Wilson DC**, Hutcheson RH, Schaffner W: Epidemic Rash in a High School: An Outbreak of Mass Sociogenic Illness. (Submitted for publication)
7. Zic J, Arzubia C, Salhany KE, Parker RA, **Wilson D**, Stricklin GP, Greer L, King LE Jr: Extracorporeal Photophoresis for the Treatment of Cutaneous T Cell Lymphoma. *JAAD* 27:729, 1992.
8. Anderson PC, Burnett JW, **Wilson DC**: Bites and stings: It's that time of year. *Patient Care* 26:79, 1992.
9. **Wilson DC**, Jester J, King LE Jr: Erythroderma and Exfoliative Dermatitis. *Clinics in Dermatology* 11:67, 1993.
10. Zic JA, Stricklin GP, Greer JP, Kinney MC, Shyr Y, **Wilson DC**, King LE Jr: Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. *J Am Acad Dermatol* 35:935, 1996.
11. Sams HH, Hearth SB, Long LL, **Wilson DC**, Sanders DH, King LE Jr.: Nineteen documented cases of *Loxosceles reclusa* envenomation. *J Am Acad Dermatol* 44:603, 2001.
12. Lucky A, Jorizzo JL, Rodriguez D, Jones TM, Stewart DM, Tschen EH, Kanof NB, MillerBH, **Wilson DC**, Loven KH. Efficacy and Tolerance of Adapalene Cream 0.1% Compared with Its Cream Vehicle for the Treatment of Acne Vulgaris. *Cutis* 68:34, 2001.
13. Machtinger LA, Kaibey K, Lim J, Loven KH, Rist TE, **Wilson DC**, Parizadeh DD, SeftonJ, Hollan JM, Walker PS: Histological effects of tazarotene 0.1% cream vs. vehicle on photodamaged skin: a 6-month, multicentre, double-blind, randomized, vehicle-controlled study in patients with photodamaged facial skin. *Br J Dermatol* 151:1245, 2004.
14. Thiboutot D, Pariser DM, Egan N, Flores J, Herndon JH Jr, Kanof NB, Kempers SE, Maddin S, Poulin YP, **Wilson DC**, Hwa J, Liu Y, Graeber M; Adapalene Study Group: Adapalene Gel 0.3% for the Treatment of Acne Vulgaris: A Multicenter, Randomized, Double-Blind, Controlled, Phase III Trial. *JAAD* 54:242, 2006.
15. Belsito D, **Wilson DC**, Warshaw E, Fowler J, Ehrlich A, Anderson B, Strober BE, Willetts J, Rutledge ES: A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. *J Am Acad Dermatol* 55:40, 2006.
16. Berger R, Rizer R, Barba A, **Wilson D**, Stewart D, Grossman R, Nighland M, Weiss J: Tretinoin Gel Microspheres 0.04% Versus 0.1% in Adolescents and Adults with Mild to Moderate Acne Vulgaris: a 12-week, Multicenter, Randomized, Double-Blind, Parallel-Group, Phase IV Trial. *Clinical Therapeutics* 29:1086, 2007.

Publications:
(Continued)

17. Berger R, Barba A, Fleischer A, Leyden JJ, Lucky A, Pariser D, Rafal E, Thiboutot D, **Wilson D**, Grossman R, Nighland M: A Double-Blinded, Randomized, Vehicle-Controlled, Multicenter, Parallel-Group Study to Assess the Safety and Efficacy of Tretinoin Gel Microsphere 0.04% in the Treatment of Acne Vulgaris in Adults. *Cutis* 80:152, 2007.
18. Raimer S, Maloney JM, Bourcier M, **Wilson D**, Papp K, Siegfried E, Garrett S: Efficacy Safety of Dasone Gel 5% for the Treatment of Acne Vulgaris in Adolescents. *Cutis* 81:171, 2008.
19. Tanghetti, E, Kircik, L, **Wilson D**, Dhawan, S: Solubilized Benzoyl Peroxide Versus Benzoyl Peroxide/Clindamycin in the Treatment of Moderate Acne. *Journal of Drugs in Dermatology* 7:534, 2008
20. Piette, WW, Taylor S, Paizer D, Jarratt M, Sheth P, **Wilson D**: Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. *Arch Dermatol* 144(12):1564, 2008
21. Kircik L, Green L, Thiboutot D, Tanghetti E, **Wilson D**, Dhawan S, Parr L: Comparing a Novel Solubilized Benzoyl Peroxide Gel with Benzoyl Peroxide/Clindamycin: Final Data from a multicenter, Investigator-blind, randomized study. *J Drugs Dermatol* 8:812, 2009
22. Pariser D, Bucko A, Fried R, Jarratt M, Kempers S, Kircik L, Lucky A, Rafal E, Rendon M, Weiss J, Wilson D, Rossi A, Ramaswamy R, Nighland M: Tretinoin Gel Microsphere Pump 0.04% Plus 5% Benzoyl Peroxide Wash for Treatment of Acne Vulgaris: Morning/Morning Regimen is as effective and Safe as Morning/Evening Regimen. *J Drugs Dermatol* 9:1, 2010

Editorials:

1. **Wilson DC**, King LE Jr: Intriguing webs in urban wilderness. *Journal of Wilderness Medicine* 2:55, 1991

Letters to Editor:

1. **Wilson DC**, King LE Jr: Letter to Editor. *Trans. Roy. Soc. Trop. Med. Hyg.* 85:410, 1991. Book Chapters:
2. **Wilson DC**, Leyva W, King LE Jr.: Arthropods and Arthropod Bites. In *Dermatology in General Medicine*. Fitzpatrick et al. Ed. McGraw Hill, 1993. Revised for republication 1999. Revised for republication 2003.

Poster Presentations:

1. Safety and Efficacy Comparison of Adapalene Cream, 0.1% and Cream Vehicle in the Treatment of Acne Vulgaris. B. Miller, MD, T. Jones MD, J. Jorizzo, MD, N. Kanof, MD, K. Loven MD, A. Lucky MD, D. Rodriques MD, D. Stewart DO, E. Tschen MD, **D. Wilson MD**, M. Poncet M.S., A. Clucas MRCP, C. Loesche MD, M. Baker BS. Presented at the Summer Session of the American Academy of Dermatology, July 2000, Nashville, TN.
2. Safety and Efficacy Comparison of Adapalene Gel 0.1% versus Tretinoin Cream 0.05% in Subjects with Acne Vulgaris. WJ Cunliffe MD, W Danby MD, MH Gold MD, D Gratton MD, A Greenspan MD, MT Jarratt MD, J Meynadier MD, RK Scher MD DM Stewart DO, LJ Swinyer MD, DM Thiboutot MD, **D Wilson MD**, JE Wolf Jr. MD, MR Tuley PhD, MD Baker BS, A Clucas FRCP. Presented at the Annual Meeting of the American Academy of Dermatology, March 2001, Washington, DC

Publications:
(Continued)

3. Histological effects of tazarotene cream 0.1% versus vehicle in photodamaged skin. A 6-month, multi-center, double-blind, parallel-group study in patients with photodamaged facial skin. Machtinger LA, Kaidbey K, Lim J, Loven KH, Rist TE, **Wilson DC**, Parazideh D, Sefton J, Holland M, Walker PS. Presented at the Annual Meeting of the American Academy of Dermatology, February 2002, New Orleans, LA
4. The efficacy and safety of Adapalene gel, 0.3% in acne: a dose ranging study. Graeber M, Tschen E, **Wilson D**, Jones T. Presented at the Annual Meeting of the American Academy of Dermatology, February 2004, Washington DC
5. Clinical Irritation Patch Tests of Retinoid Formulations. **Wilson DC**, Stevens V. Presented at the Annual Meeting of the American Academy of Dermatology, February 2004, Washington DC
6. Double-blind, randomized, placebo-controlled, multicenter study to assess two strengths of tretinoin microsphere gel (TMG) in the treatment of acne vulgaris. Eichenfield L, Greenspan A, Katz HI, Leyden J, Lucky A, Pariser D, Rafal E, Rodrigues D, Shavin J, Webster G, **Wilson D**, Barsanti F, Kruleski L, Going J, Armstrong R. Presented at that Annual Meeting of the American Academy of Dermatology.
7. Double-blind, randomized, vehicle-controlled, multicenter study to assess the safety and efficacy of tretinoin microsphere gel (TMG) 0.04% in the treatment of acne vulgaris. Berger B, Eichenfield L, Jorizzo J, Lucky A, Martin A, Rafal E, Reynolds M, Shalita A, Weiss J, **Wilson D**, Barsanti F, Kruleski L, Goin J, Armstrong R. Presented at the Annual Meeting of the American Academy of Dermatology.
8. A prospective clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. Belsito D, **Wilson D**, Warshaw E, Fowler J. Presented at the Annual Meeting of the American Academy of Dermatology, March 2006, San Francisco, CA.

Abstracts:

1. Greer JP, Salhany KE, Fields JP, King LE Jr., Malcolm AW, Flexner BL, Graber SE, Dufresne RG, Latour DL, **Wilson DC**, Siegel JM, Flexner JM, Stein RS, Collins R, and Cousar JB: Cell Lymphoma (CTCL). *Blood* 68:238A, 1986. Presented American Society of Hematology 28th Annual Meeting, San Francisco, December 1986.
2. Wharton M, Wadley F, Hager B, **Wilson D**, Hutcheson R, Schaffner W: Mass Psychogenic Illness in a High School, Tennessee (unpublished) Presented 1987 EIS Conference.
3. **Wilson DC**, Werth SG: Ulcerative Herpes Simplex Type II in a patient with Evan's syndrome. *South Med J* 82:S15, 1989. Presented at the Southern Medical Association 83rd Annual Meeting, Washington, DC, November 1989.
4. **Wilson DC**, Gross AS: Cutaneous Anesthesia Associated with a Brown Recluse Spider Bite. *South Med J* 82:S12, 1989. Presented to Southern Medical Association 83rd Annual Meeting, Washington DC, November 1989.

Continuing Education:

2017	Investigator IGA and Lesion Counting Study Specific for Acne
2016	Clinician Reported Photonumeric Cellulite Severity Scale for Buttock and Thigh Study Specific for Cellulite
2016	Clinical Assessments of Tinea Pedis Study Specific for Tinea Pedis
2016	Good Clinical Practices (most recent) Study Specific Investigator Meetings
2015	Self Training ERF Standard Operating Procedures
2015	Investigator Global Assessment, BSA and Target Lesion Signs of Psoriasis Study Specific for Psoriasis
2015	The National Institutes of Health (NIH) (most recent) Protecting Human Research Participants
2015	Investigator Global Assessments (IGA) and Lesion Counting Study Specific for Acne
2014-2015	General Sponsor Training ICH GCP Investigator Training Investigator Safety Training Safety Reporting in Clinical Studies GCP Training for Investigator and Study Site Staff
2014	In-house Training ERF Standard Operating Procedures
2014	Facial Lesion Count Exercise Study Specific for Acne
2013	In-house Training ERF Standard Operating Procedures
2012	Investigator Global Assessment, BSA and Target Lesion Signs of Psoriasis Study Specific for Psoriasis
2012	The NIH Office of Clinical Research Training and Medical Education Clinical Research Training
2012	Evaluator Global Assessments (EGSS) and Lesion Count Assessments Study Specific for Acne
2011	Investigator's Global Assessment (IGA) and Lesion Counting Harmonization Study Specific for Rosacea
2010	Clinician's Erythema Assessment (CEA) Harmonization Study Specific for Rosacea
2010	"Guide to Good Clinical Practice" Monthly Newsletters Thompson Publishing Group, Inc.

Electronic Data Capture Training:

2017	Inform GTM 6.0, Medrio, Oracle, Medidata
2016	Medidata Rave, Trialdriver
2015	eCaselink, Medrio, Inform 6.0, Axiom Fusion, Cicys
2014	eClinicalOS, Inform 5.5, Medidata Rave, Medidata Balance
2013	dsg eCaselink, Sequence WebEDC, Medrio
2012	Oracle Onsite 4.6.5, Medidata, iMedidata, TrialMaster v4, Sequence WebEDC
2010	Oracle RDC4.5.3, Inform 5.0
2009	Timeaus, Oracle
2008	eCaseLink
2007	TrialMaster v3.0 (OmniComm Systems)
2007	InForm 4.5
2006	Numoda, webFORMS, Oracle
2004	Axiom

Study Experience:

Phase I:
Repeat Insult Patch Test
Modified Repeat Insult Patch Test
10 and 21 Day Cumulative Irritation
Photocontact Allergy
Phototoxicity

Phases II, III, IV:
Mild to Severe Acne (topical and light therapy)
Actinic Keratosis
Seborrheic Keratosis
Psoriasis (topical and biologic)
Atopic Dermatitis/Eczema (topical and oral)
Onychomycosis (topical and oral)
Mild to Severe Dandruff (topical and oral)
Seborrheic Dermatitis
Basal Cell Carcinoma
Squamous Cell Carcinoma
Photodamaged Facial Skin
Solar Lentigines
Tinea Versicolor
Alopecia
Tinea Pedis
Nickle Allergy
Hair Removal (light based, topical)
Aging Skin
Rosacea
Tinea Cruris
Cellulite
Warts

Post-Marketing:
Eczema (biologic)
Psoriasis (biologic)

OTC & Device:

Skin Biopsies
Hair Growth
Healthy Skin
Corns/Calluses
Shoe Insoles/Inserts
Use-Irritancy (antiperspirants, shave gels, depilatories, cosmetics, etc.)
Feminine Hygiene

OTC & Device:
(Continued)

Constipation
Dry Skin (Perception)
Injectable – Product - Safety Analysis
Pseudofolliculitis Barbae
Skin Tags
Warts
Anti-Aging
Long-Range UVA